Baxter International (NYSE:BAX – Get Free Report) posted its earnings results on Thursday. The medical instruments supplier reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19, FiscalAI reports. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. During the same quarter in the prior year, the company posted $0.59 earnings per share. Baxter International’s revenue for the quarter was up 5.3% compared to the same quarter last year. Baxter International updated its FY 2026 guidance to 1.950-2.150 EPS.
Here are the key takeaways from Baxter International’s conference call:
- Second-quarter sales rose 5% organically to approximately $3 billion, with growth across all segments and geographies. Advanced Surgery and drug compounding were standout contributors, while hospital demand and order books remained solid.
- Baxter raised its 2026 organic sales-growth outlook to 2%-3% and adjusted EPS guidance to $1.95-$2.15 per share, helped by stronger year-to-date performance and a $75 million tariff refund.
- Adjusted EPS declined 5% to $0.56, reflecting higher-cost inventory, an unfavorable prior-year accounting comparison, and mix pressure from fast-growing but lower-margin drug compounding. Management expects operating margins to improve in the second half as these headwinds roll off and cost actions take effect.
- The Novum IQ LVP infusion pump remains subject to a shipment and installation hold while Baxter conducts verification testing and works with regulators. Injectable sales and parts of the pharmaceutical portfolio also remain constrained by supply issues, including problems at a contract manufacturer.
- Second-quarter free cash flow reached $181 million, bringing year-to-date free cash flow to $257 million. Management is increasingly confident it can reduce net leverage to approximately 3x by year-end, potentially creating capacity for tuck-in acquisitions or share repurchases.
Baxter International Stock Performance
Shares of BAX stock traded down $0.51 on Friday, hitting $26.24. The company had a trading volume of 2,988,548 shares, compared to its average volume of 8,347,267. Baxter International has a twelve month low of $15.73 and a twelve month high of $30.00. The company has a quick ratio of 1.23, a current ratio of 1.85 and a debt-to-equity ratio of 1.43. The firm has a market cap of $13.55 billion, a P/E ratio of -12.33, a price-to-earnings-growth ratio of 4.00 and a beta of 0.62. The company has a 50-day moving average price of $21.20 and a 200-day moving average price of $19.56.
Baxter International Dividend Announcement
Key Headlines Impacting Baxter International
Here are the key news stories impacting Baxter International this week:
- Positive Sentiment: Strong second-quarter results and raised outlook supported the recent rally. Baxter reported adjusted earnings of $0.56 per share, exceeding the approximately $0.36–$0.37 consensus, while revenue reached $2.96 billion versus estimates near $2.80 billion. Sales increased 5.3% year over year, helped by demand for IV solutions and strength in drug compounding. Management raised fiscal 2026 guidance to $1.95–$2.15 in EPS and $11.6–$11.7 billion in revenue, above consensus expectations. Baxter raises annual profit forecast on strong demand for IV solutions
- Positive Sentiment: Citigroup upgraded BAX from “sell” to “neutral” and raised its price target to $28 from $17. The move indicates that improving operating performance and recovery prospects have reduced the bank’s bearish outlook. Citigroup analyst action
- Neutral Sentiment: Wells Fargo raised its price target to $23 from $19 but maintained an “equal weight” rating. The new target remains below the current trading level, suggesting the firm sees limited near-term upside despite Baxter’s improved fundamentals. Wells Fargo analyst action
- Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, payable October 1 to shareholders of record August 28. The annualized yield is approximately 0.2%, so the dividend is unlikely to be a major stock-price catalyst.
- Negative Sentiment: Profit-taking and valuation concerns may be weighing on the shares after the earnings surge. Although the earnings beat and guidance increase were encouraging, adjusted earnings declined from $0.59 a year earlier, margins remain under pressure from tariffs and inflation, and analyst targets are still mixed. Wells Fargo’s target implies downside from current levels, while broader analyst sentiment remains largely neutral. Baxter shares jump after beat and raise
Institutional Trading of Baxter International
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Baxter International by 21.4% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 4,293 shares during the period. Vestor Capital LLC grew its position in shares of Baxter International by 1,340.3% during the 4th quarter. Vestor Capital LLC now owns 40,645 shares of the medical instruments supplier’s stock valued at $777,000 after acquiring an additional 37,823 shares during the period. Baird Financial Group Inc. increased its stake in shares of Baxter International by 3.2% in the 2nd quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock valued at $1,588,000 after purchasing an additional 1,604 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Baxter International by 5.5% in the 2nd quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock valued at $1,633,000 after purchasing an additional 2,813 shares in the last quarter. Finally, State of Tennessee Department of Treasury raised its holdings in Baxter International by 99.1% in the 4th quarter. State of Tennessee Department of Treasury now owns 111,858 shares of the medical instruments supplier’s stock worth $2,245,000 after purchasing an additional 55,674 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.
Analyst Upgrades and Downgrades
BAX has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised their price objective on Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Zacks Research cut Baxter International from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings raised Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. TD Cowen boosted their price target on Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday. Finally, Wells Fargo & Company upped their price objective on shares of Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a report on Friday. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $22.45.
Get Our Latest Stock Analysis on BAX
Baxter International Company Profile
Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.
In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.
Read More
- Five stocks we like better than Baxter International
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
